Novavax (NASDAQ: NVAX) announced that it received $1.6 funding for the development of a vaccine for COVID-19, which continues to spread across the United States and around the world.
In the U.S., 2,932,596 people have been infected by the virus and 130,133 already died as of July 7, according to data from the Centers for Disease Control and Prevention (CDC).
Helping Novavax complete its clinical studies for COVID-19 vaccine candidate
According to the biotechnology company, the funding came from the U.S. government’s Operation Warp Speed (OWS) program that aims to start delivering millions of doses of a safe and effective vaccine for COVID-19 next year.
OWS provided the $1.6 billion funding to help Novavax complete the late-stage clinical studies necessary to determine the efficacy and safety of its COVID-19 vaccine candidate, NVX-CoV2373.
Novavax’s clinical studies include a Phase 3 clinical trial with up to 30,000 subjects starting in the fall of 2020.
In May, the biotechnology company started the Phase 1/2 clinical trial of NVX-CoV2373 in 130 healthy participants 18 to 59 years of age in Australia. It is expecting to have the preliminary immunogenicity and safety results by the end of this month.